Bayer’s elinzanetant meets all primary and key secondary endpoints in OASIS 1 and 2 Phase III studies
AskBio Phase Ib trial of AB-1005 gene therapy in patients with Parkinson’s disease meets primary endpoint
Bayer raises over $1 million in support of Food Banks Canada
Bayer Named One of Canada’s Top 100 Employers and Most Admired™ Corporate Cultures
Global coalition for World Contraception Day encourages young people to make informed contraception decisions
We research, develop and market innovative products that improve the health of people and plants. Our business comprises three core divisions and one business unit. Learn more about it here.